$42.25 +1.45 (%) Alnylam Pharmaceuticals Inc - NASDAQ

Dec. 9, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Market Reversal In Biotech But Healthcare Stocks Are Still Muddled

    TalkMarkets | Nov. 29, 2016 | 22:56PM EST
  2. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets | Nov. 16, 2016 | 15:30PM EST
  3. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  4. IPO Preview: Ra Pharmaceuticals

    TalkMarkets | Oct. 26, 2016 | 01:02AM EST
  5. Biotechnology Bear Market: Trends To Watch For A 2016 Q4 Rally

    TalkMarkets | Oct. 12, 2016 | 23:02PM EST
  6. Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

    TalkMarkets | Oct. 12, 2016 | 11:14AM EST
  7. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  8. Morning Call For October 6, 2016

    TalkMarkets | Oct. 6, 2016 | 08:17AM EST
  9. Biotech Stocks Recovering From Last Week’s Free Fall

    TalkMarkets | Oct. 5, 2016 | 23:06PM EST
  10. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  11. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  12. Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'

    Benzinga | Jan. 11, 2016 | 13:57PM EST
  13. Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B

    Benzinga | Dec. 7, 2015 | 10:30AM EST
  14. Breakaway Gaps By Stocks Can Be Scary But Profitable

    IBD | Dec. 3, 2015 | 17:58PM EST
  15. Leerink Highlights Biotechs Poised To Benefit From ASH Conference

    Benzinga | Nov. 30, 2015 | 13:13PM EST
  16. Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam ...

    GuruFocus | Nov. 17, 2015 | 10:50AM EST
  17. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga | Nov. 5, 2015 | 10:25AM EST
  18. Chardan Sees Promise Of ALN-PCSsc, Initiates The Medicines Co. With Buy

    Benzinga | Nov. 4, 2015 | 07:50AM EST
  19. Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

    Benzinga | Nov. 3, 2015 | 05:01AM EST
  20. Benzinga's Top Initiations

    Benzinga | Oct. 23, 2015 | 07:20AM EST
  21. Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

    Benzinga | Oct. 8, 2015 | 15:01PM EST
  22. Julian Robertson Boosts His Stakes in JD.com, Netflix

    GuruFocus | Oct. 6, 2015 | 13:44PM EST
  23. Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

    Benzinga | Oct. 6, 2015 | 13:08PM EST
  24. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD | Sep. 24, 2015 | 09:51AM EST
  25. Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias

    Benzinga | Sep. 15, 2015 | 06:00AM EST
  26. Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | Sep. 14, 2015 | 03:53AM EST
  27. 4 Biotechs Piper Jaffray Is Buying On The Pullback

    Benzinga | Aug. 26, 2015 | 14:27PM EST
  28. Here's One Biotech Stock JMP Analysts Are Very Bullish On

    Benzinga | Aug. 26, 2015 | 08:31AM EST
  29. Benzinga's Top Initiations

    Benzinga | Aug. 11, 2015 | 08:45AM EST
  30. Benzinga's Top Downgrades

    Benzinga | Aug. 7, 2015 | 08:34AM EST
  31. 5 Biotech Stocks On Deck With The FDA

    Benzinga | Jun. 30, 2015 | 12:39PM EST
  32. Julian Robertson Adds 16 New Stakes to Portfolio

    GuruFocus | Jun. 23, 2015 | 17:39PM EST
  33. Gurus Purchase Tekmira Pharmaceuticals in Q1

    GuruFocus | Jun. 19, 2015 | 16:57PM EST
  34. JMP Sees A 'Negative Market Tone' In Biotechnology

    Benzinga | Jun. 15, 2015 | 12:31PM EST
  35. Alnylam Reports Data on Potential Alexion Rival Drug

    IBD | Jun. 12, 2015 | 11:38AM EST
  36. US Stock Futures Slide Ahead Of Economic Data

    Benzinga | Jun. 12, 2015 | 06:22AM EST
  37. Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

    Benzinga | Jun. 12, 2015 | 05:05AM EST
  38. After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma

    Benzinga | May. 16, 2015 | 08:50AM EST
  39. Alnylam Pharmaceuticals

    IBD | Apr. 21, 2015 | 17:48PM EST
  40. Alnylam Says Neurological Drug Passes Midstage Study

    IBD | Apr. 21, 2015 | 12:22PM EST
  41. Morning Market Gainers

    Benzinga | Apr. 21, 2015 | 08:45AM EST
  42. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 21, 2015 | 07:13AM EST
  43. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga | Apr. 20, 2015 | 12:44PM EST
  44. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 15:31PM EST
  45. Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3

    Benzinga | Apr. 13, 2015 | 10:01AM EST
  46. Benzinga's Top Initiations

    Benzinga | Feb. 27, 2015 | 09:29AM EST
  47. Microsoft, Bank Of New York And Others Insiders Have Been Buying

    Benzinga | Feb. 2, 2015 | 08:57AM EST
  48. Deutsche Bank's Top Biotech Picks For 2015

    Benzinga | Jan. 22, 2015 | 11:09AM EST
  49. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher

    Benzinga | Jan. 21, 2015 | 15:10PM EST
  50. 4 More Biotech Secondaries Traders Are Watching

    Benzinga | Jan. 21, 2015 | 13:38PM EST
Trading Center